Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Early Ovarian Tumor Detection Discovery to Aid Development of Screening Test

By LabMedica International staff writers
Posted on 25 May 2010
Ovarian cancer kills nearly 15,000 women in the United States alone each year, and less than half of the women diagnosed with the disease survive five years. More...
A screening test that detects ovarian cancer early, when it is still treatable, would have the potential of reducing the high mortality, yet scientists have not known where the tumors originate or what they look like. Now, researchers believe they have solved both obstacles.

New research, published on April 26, 2010, in the journal in PLoS ONE, revealed that researchers from Fox Chase Cancer Center (Philadelphia, PA, USA) have uncovered early tumors and precancerous lesions in cysts that fold into the ovary from its surface, called inclusion cysts. "This is the first study giving very strong evidence that a substantial number of ovarian cancers arise in inclusion cysts and that there is indeed a precursor lesion that you can see, put your hands on, and give a name to,” stated Jeff Boyd, Ph.D., chief scientific officer at Fox Chase and lead author on the study, which also involved colleagues at Memorial Sloan-Kettering Cancer Center (New York, NY, USA). "Ovarian cancer most of the time seems to arise in simple inclusion cysts of the ovary, as opposed to the surface epithelium.”

Clinicians and researchers have been looking for early ovarian tumors and the precancerous lesions from which they develop for years without success. In this study, Dr. Boyd and colleagues used a combination of conventional microscopy and molecular approaches to reveal the early cancers.

"Previous studies only looked at this at the morphologic level, looking at a piece of tissue under a microscope,” Dr. Boyd said. "We did that but we also dissected away cells from normal ovaries and early stage cancers, and did genetic analyses. We showed that you could follow progression from normal cells to the precursor lesion, which we call dysplasia, to the actual cancer, and see them adjacent to one another within an inclusion cyst.”

To learn where and how the tumors arise, the team examined ovaries removed from women with BRCA mutations, who have a 40% lifetime risk of developing ovarian cancer, and from women without known genetic risk factors. In both groups, the researchers discovered that gene expression patterns were considerably different in cells in the inclusion cysts compared to the normal surface epithelium cells, including increased expression of genes that control cell division and chromosome movement.

Moreover, when the investigators used a technique called fluorescence in-situ hybridization (FISH), which can be used to identify individual chromosomes in cells, they noticed that cells from very early tumors and precursor lesions frequently carried extra chromosomes. In fact, the team found that 9% of the normal cells isolated from the cysts had extra chromosomes, even though the tissue appeared completely benign under the microscope. By contrast, virtually none of the cells isolated from the surface of the ovary, which was previously believed to be the site of early ovarian cancers, carried extra chromosomes.

With these new data on the origin of ovarian cancer, Dr. Boyd and others can now begin to develop screening tests, perhaps based on molecular imaging, which could be utilized to detect early ovarian cancers in asymptomatic women.

Related Links:

Fox Chase Cancer Center
Memorial Sloan-Kettering Cancer Center



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Rapid Test Reader
DIA5000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.